BioNTech Archives

biontech cancer vaccine mrna immunotherapy

News and Trends 9 Jul 2019

BioNTech Raises Whopping €290M to Fund Personalized mRNA Vaccines for Cancer

In one of the biggest ever funding rounds in European biotech, the German company BioNTech has raised a Series B of €289.5M ($325M) to develop individualized cancer vaccines. BioNTech will use the money to fuel the clinical development of the company’s lead program — an individualized mRNA-based immunotherapy for treating melanoma, which completed a phase […]

July 9, 2019 - 3 minutesmins - By Jonathan Smith

News and Trends 7 Jul 2019

European Biotech: The Insider View

How has CRISPR changed drug development? How do you negotiate a good partnership? What are some of the hard decisions to make in founding a biotech? These are some of the questions that industry experts answered at Labiotech’s first Insider Day. Held exclusively for members, Labiotech’s first Insider Day aimed to explore the different aspects […]

July 7, 2019 - 10 minutesmins - By Jonathan Smith

News and Trends 7 Jan 2019

Sanofi Invests €80M in mRNA Cancer Vaccine Company

Sanofi is to make an €80M equity investment in the German biotech BioNTech, and the two have agreed to co-develop a cancer vaccine based on injecting messenger RNA into solid tumors. This agreement is an extension of Sanofi and BioNTech’s collaboration, which began in 2015. The two companies will continue to co-develop and co-commercialize a candidate […]

January 7, 2019 - 3 minutesmins - By Jonathan Smith

News and Trends 20 Dec 2018

Personalized Immunotherapy for Brain Cancer Succeeds in Clinical Trials

A European trial has proved the feasibility and efficacy of treating cancer with a personalized immunotherapy tailored to each patient. The phase I/II trial, run across six European centers, tested a combination of two personalized vaccines in patients with glioblastoma, an aggressive form of brain cancer. The first vaccine was designed to immunize the patients […]

December 20, 2018 - 3 minutesmins - By Clara Rodríguez Fernández

News and Trends 11 Dec 2018

What Does the Largest Biotech IPO Ever Mean for European Biotech?

With a massive €530M ($604M) raised, US-based Moderna has made a record biotech IPO. The news could give a significant boost to developers of messenger RNA, a technology that is still several years away from the market. Entering the Nasdaq with a €7B ($8B) market cap, Moderna made history last Friday with a technology that […]

December 11, 2018 - 3 minutesmins - By Clara Rodríguez Fernández

In Depth 1 Oct 2018

Could These Innovative Flu Vaccines Prevent Deaths From Deadly Outbreaks?

Despite more than a century of scientific endeavour, influenza remains one of the most deadly infectious diseases worldwide. Across Europe, many biotechs are working on novel solutions that could dramatically improve the protection rates offered by current vaccines. Some may even lead to the holy grail of influenza research – a universal flu vaccine. Each […]

October 1, 2018 - 8 minutesmins - By David Cox

News and Trends 16 Aug 2018

Pfizer Offers €374M for German mRNA Flu Vaccine

BioNTech, based in Mainz, Germany, has entered into a partnership with Pfizer worth up to $425M (€374M) to develop an mRNA-based flu vaccine, which could be produced much more quickly than current flu vaccines. Messenger RNA (mRNA) is one of the building blocks living organisms use to create proteins from genes. BioNTech is developing prophylactic […]

August 16, 2018 - 2 minutesmins - By Alexander Burik

Best in Biotech 20 Feb 2018

Money, Money, Money! Europe’s Best-Funded Biotechs in 2018

Besides struggling with ambitious New Year’s resolutions and post-holiday diets, January is a time where many of us re-examine our finances and budget for the year ahead. With money on the brain, we thought it would be a good time to do a roundup of Europe’s best-funded private biotechs. With over €400M raised to date, […]

February 20, 2018 - 11 minutesmins - By Karen O’Hanlon Cohrt

News and Trends 9 Jan 2018

Scancell and BioNTech Will Combine Their Expertise to Fight Cancer

Scancell has brought in BioNTech to develop T-cell receptors against specific target proteins in cancer cells, opening the door to new cancer treatments that target them. Scancell works on immunotherapies for the treatment of cancer and it has announced that it will come together with Europe’s largest private biopharma, BioNTech, to develop T-cell receptor (TCR)-based therapies. […]

January 9, 2018 - 3 minutesmins - By Alex Dale

News and Trends 4 Jan 2018

German Biotech Raises Record $270M Series A for Individualized Cancer Therapies

BioNTech will dedicate its huge fundraising to develop personalized cancer immunotherapies using CAR-T, TCR and mRNA technologies. BioNTech is kicking off the new year with great news. The company has closed its Series A with $270M (€225M) — a record amount in Germany for such an early funding round. The fundraising was led by the […]

January 4, 2018 - 2 minutesmins - By Clara Rodríguez Fernández

moderna biontech personalized cancer vaccine

News and Trends 15 Nov 2017

US Biotech Unicorn Steps up Competition for BioNTech’s mRNA Personalized Cancer Vaccine

Moderna Therapeutics has started dosing patients with an mRNA-based personalized cancer vaccine that resembles another one being developed by BioNTech. Moderna Therapeutics has announced the start of a Phase 1 study with mRNA-4157, a therapy consisting of a cancer vaccine that is tailored to each patient’s individual tumor. In order to make this personalized treatment, […]

November 15, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 6 Nov 2017

German Biotech Teams Up with BioNTech to Boost Antibody Development

MAB Discovery and BioNTech are working together to push through the development of new antibody therapeutics using MAB’s technology platform. MAB Discovery creates monoclonal antibodies by stimulating natural antibody maturation using its own sophisticated platform. On the back of a highly productive agreement signed in 2013, BioNTech, Europe’s largest privately held biopharma, has moved to agree […]

November 6, 2017 - 1 minutemin - By Alex Dale

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us